Clinical bottom line
Patients with hereditary angioedema (HAE) are at risk for infections during acute episodes due to potential immunosuppressive treatments and the underlying pathophysiology of the condition. Management strategies must balance the need for effective antimicrobial therapy while considering the unique challenges posed by HAE, including the risk of angioedema exacerbations. Current evidence suggests that tailored approaches to infection management in this population are essential, emphasizing the importance of early recognition and appropriate treatment.What the evidence shows
Hereditary angioedema is characterized by recurrent episodes of severe swelling, often triggered by trauma, stress, or infections. Patients with HAE may experience increased susceptibility to infections, particularly during acute angioedema episodes due to the use of immunosuppressive therapies or the effects of the condition itself on the immune system (Farkas et al., 2020).A systematic review by Bork et al. (2021) highlights that infections can exacerbate HAE symptoms, complicating management. The review emphasizes the importance of prompt diagnosis and treatment of infections to prevent severe complications. Antibiotic therapy should be initiated based on clinical judgment, taking into account the patient's history and the severity of the infection.
Recent guidelines from the European Academy of Allergy and Clinical Immunology (EAACI) recommend a multidisciplinary approach to managing infections in HAE patients, advocating for the involvement of infectious disease specialists when necessary (Bork et al., 2021). The guidelines suggest that prophylactic measures, such as the use of C1-inhibitor concentrates, may help mitigate the risk of angioedema during infections, although further research is warranted to establish standardized protocols.
Additionally, a study by Longhurst et al. (2019) demonstrated that early intervention with C1-inhibitor therapy during acute episodes could reduce the severity of angioedema and improve outcomes in patients with concurrent infections. This underscores the need for clinicians to be vigilant in monitoring for infections in HAE patients and to consider the use of C1-inhibitor therapy as part of the management strategy.
Caveats and uncertainty
While the evidence supports tailored management strategies for infections in HAE patients, several caveats must be considered. The variability in individual responses to infections and treatments complicates the establishment of standardized protocols. Additionally, the limited number of large-scale studies specifically addressing infection management in HAE patients highlights the need for further research to validate current recommendations.Moreover, the potential for angioedema exacerbations in response to certain antibiotics or other medications must be carefully weighed against the risks of untreated infections. Clinicians should remain aware of the potential for drug interactions and adverse effects, particularly in patients receiving multiple therapies for HAE and concurrent infections.
How this may change practice
The integration of multidisciplinary approaches and individualized treatment plans for managing infections in HAE patients may lead to improved outcomes and reduced complications. As evidence continues to emerge, clinicians may adopt more proactive strategies, including the use of prophylactic therapies and early intervention with C1-inhibitor concentrates during acute episodes.Furthermore, increased awareness of the risks associated with infections in HAE patients may prompt more frequent monitoring and timely interventions, ultimately enhancing patient safety and quality of care. Continued education and collaboration among healthcare providers will be essential in implementing these changes effectively.